¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"selective survival bias"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® five-year survival rate ÇÑ±Û ¿À³â»ýÁ¸À²
¼³¸í   
  1. µ¿ÀÏ Áúº´ÀÇ Áø´Ü È¤Àº Ä¡·á ÈÄ, 5³âÀÌ °æ°ú µÈ µÚÀÇ »ýÁ¸ÀÚ¼öÀǠǥÇö. 2. ¾ÏÀÇ Áø´Ü ¶Ç´Â Ä¡·á µÚ¿¡ °Ë»ç¸¦ ¹Ýº¹ÇÏ¿© 5³â µ¿¾È »ì¾Æ Àִ »ç¶÷ÀÇ ¹éºÐÀ². Ä¡·á ÈÄ 5³â µ¿¾È »ýÁ¸Çϸé ÀÏ´Ü Ä¡À¯µÈ °ÍÀ¸·Î °£ÁÖÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • selective survival bias
    ¼±ÅûýÁ¸Ä¡¿ìħ, ¼±ÅûýÁ¸¿ÀÂ÷
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • selective attrition bias
    ¼±ÅüսǹÙÀ̾
  • crude survival rate
    º¸Åë»ýÁ¸À², Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • disease free survival
    ¹«º´»ýÁ¸
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • survival
    »ýÁ¸
  • survival analysis
    »ýÁ¸ºÐ¼®
  • survival curve
    »ýÁ¸°î¼±
  • survival function
    »ýÁ¸ÇÔ¼ö
  • survival rate
    »ýÁ¸À²
  • survival ratio
    »ýÁ¸ºñ
  • survival ration
    ±¸¸í½Ä·®
  • survival time
    »ýÁ¸±â°£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • selective survival bias
    ¼±ÅûýÁ¸Ä¡¿ìħ, ¼±ÅûýÁ¸¿ÀÂ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • selective cultivation
    ¼±Åùè¾ç
  • selective peripheral denervation
    ¼±Åø»ÃʽŰæÂ÷´Ü
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • selective
    Á¦ÇѼ±ÅÃ-
  • selective vagotomy
    ¼±ÅùÌÁֽŰæÀý´Ü(¼ú)
  • survival analysis
    »ýÁ¸ºÐ¼®
  • survival curve
    »ýÁ¸°î¼±
  • five-year survival rate
    ¿À³â»ýÁ¸·ü
  • survival rate
    »ýÁ¸·ü
  • survival
    »ýÁ¸
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival time
    »ýÁ¸±â°£
  • bias
    Ä¡¿ìħ, Æí°ß
  • Berkson's bias
    ¹÷½¼Ä¡¿ìħ
  • confounding bias
    ±³¶õÄ¡¿ìħ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • selective attrition bias
    ¼±ÅüսǿÀÂ÷
  • ascertainment bias
    È®ÀιÙÀ̾
  • survival analysis
    »ýÁ¸ºÐ¼®
  • bias
    ¹ÙÀ̾, Ä¡¿ìħ
  • constant bias
    »óÁ¸ÆíÀç
  • design bias
    ¼³°è¹ÙÀ̾
  • detection bias
    ¹ß°ß¹ÙÀ̾
  • information bias
    Á¤º¸¹ÙÀ̾
  • interviewer bias
    Á¶»çÀÚ¹ÙÀ̾
  • lead-time bias
    Á¶±â¹ß°ß±â°£¹ÙÀ̾
  • length bias
    ±â°£Â÷À̹ÙÀ̾
  • measurement bias
    ÃøÁ¤¹ÙÀ̾
  • observer bias
    °üÂûÀÚ¹ÙÀ̾
  • proportional bias
    ºñ·ÊÆíÀç
  • recall bias
    ȸ»ó¹ÙÀ̾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • analyltical bias
    ºÐ¼®Æí°ß
  • frequency selective fat suppression technique
    Á֯ļö ¼±Åà Áö¹æ ¾ïÁ¦(±â)¹ý
  • highly selective vagotomy
    °í¼±ÅùÌÁֽŰæÀý´Ü¼ú.
  • proportional bias
    ºñ·ÊÆíÀç(ÝïÖÇø¶î¤)
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • platelet survival measurement
    Ç÷¼ÒÆÇ»ýÁ¸´ÉÃøÁ¤
  • probability of survival
    »ýÁ¸(È®)·ü(Ë×Ì¡ Ì·Ëô).
  • red blood cell survival test
    ÀûÇ÷±¸¼ö¸í½ÃÇè(îåúìϹáøÙ¤ãËúÐ).
  • relative survival rate
    »ó´ë»ýÁ¸À²
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • selective attrition bias
    ¼±ÅÃÀû ¼Õ½Ç¿ÀÂ÷
  • analyltical bias
    ºÐ¼®Æí°ß
  • bias
    Æí°ß
  • bias
    Ä¡¿ìħ, ¹ÙÀ̾, ÆíÀç
  • constant bias
    »óÁ¸(¼º)ÆíÀç
  • proportional bias
    ºñ·ÊÆíÀç(ÝïÖÇø¶î¤)
  • selection bias
    ¼±ÅÃ(¼±¹ß, ¼±Á¤)¿ÀÂ÷
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • cell survival curve
    ¼¼Æ÷»ýÁ¸°î¼±
  • combat survival
    ÀüÅõ»ýÁ¸(¡­ßæðí).
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • desert survival
    »ç¸·»ýÁ¸(Ë×ËÎË×Ì¡).
  • disease free survival
    ¹«º´»ýÁ¸
  • erythrocyte survival
    ÀûÇ÷±¸»ýÁ¸
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • selective mass chemotherapy
    ¾ç¼ºÀÚÁý´ÜÄ¡·á
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • exponential survival curve
    Áö¼ö »ýÁ¸ °î¼± (ò¦â¦ßæðíÍØàÊ)
  • survival curve
    »ýÁ¸°î¼± (ßæðíÍØàÊ)
  • ion selective electrode
    À̿¼±ÅÃ(àÔ÷É) Àü±Ø(ï³Ð¿)
  • selective marker
    ¼±Åüº Ç¥Áö(àÔ÷Éàõøöò½)
  • selective plating
    ¼±ÅÃ(àÔ÷É) ±ò±â
  • selective system
    ¼±ÅÃ(àÔ÷É) ½Ã½ºÅÛ
  • selective theory
    ¼±ÅÃÀÌ·Ð(àÔ÷É×âÖå)
  • selective toxicity
    ¼±ÅÃÀûµ¶¼º(àÔ÷ÉîÜÔ¸àõ)
  • selective varient
    ¼±ÅÃÀûº¯ÀÌÁ¾(àÔ÷ÉîÜܨì¶ðú)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bias
    Ä¡¿ìħ, ¹ÙÀ̾, ÆíÀç, ºñƲ¸²
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival
    »ýÁ¸
  • frequency selective fat suppression technique
    Á֯ļö¼±Åà Áö¹æ¾ïÁ¦(±â)¹ý
  • selective
    ¼±ÅÃÀûÀÎ
  • selective angiogram
    ¼±ÅÃÀûÇ÷°üÁ¶¿µ»ó
  • selective angiograph
    ¼±ÅÃÀûÇ÷°üÁ¶¿µ»çÁø
  • selective arteriography
    ¼±ÅÃÀûµ¿¸ÆÁ¶¿µ¼ú
  • selective excitaion
    ¼±Åÿ©±â
  • slice selective excitation
    ÀýÆí¼±Åÿ©±â
  • water selective excitation
    ¹°ºÐÀÚ¼±Åÿ©±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CSR central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie...
SVA selective vagotomy and antrectomy; selective visceral angiography; sequential ventriculoatrial [paci...
5 YSR 5 Year Survival Rate
YSR Year Survival Rate
CDS cardiovascular surgery; catechol-3, 5-disulfonate; caudal dysplasia syndrome; Chemical Data System; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
B bias
CHESS Chemical shift selective
DS Directionally selective
HSV Highly selective vagotomy
ISE Ion-Selective Electrode
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bias
    Ä¡¿ìħ, ¹ÙÀ̾, ÆíÀç
    ü°èÀûÀÎ °ú¿À, ÃßÁ¤ÀÚÀÇ ¿¹ÃøÄ¡¿Í ÆÄ¶ó¹ÌÅÍÄ¡ »çÀÌÀÇ ¿ÀÂ÷.
  • cell survival curve
    ¼¼Æ÷ »ýÁ¸ °î¼±
  • jungle survival
    Á¤±Û »ýÁ¸
  • survival
    »ýÁ¸
  • survival rate
    »ýÁ¸À²
  • frequency selective fat suppression technique
    ÁÖÆÄ ¼ö ¼±Åà Áö¹æ ¾ïÁ¦ ±â¹ý, Á֯ļö ¼±Åà Áö¹æ ¾ïÁ¦ ±â¹ý
  • prophylactic selective grinding
    ¿¹¹æÀû »èÁ¦
  • selective absorption
    ¼±Åà Èí¼ö
    ¹°ÁúÀÌ ¾î¶² Áøµ¿¼ö ¹üÀ§ÀÇ ºû¸¸À» ƯÈ÷ °­ÇÏ°Ô Èí¼öÇÏ´Â Çö»ó. ÀÌ °æ¿ìÀÇ Áøµ¿¼ö´Â °¢ ¹°ÁúÀÇ °íÀ¯ÇÑ Æ¯¼ºÀ̹ǷÎ, ¹°ÁúÀ» Åõ°úÇÑ ºûÀÇ ½ºÆåÆ®·³Àº ±× ¹°Áú ƯÀ¯ÀÇ Èí¼ö ½ºÆåÆ®·³ÀÌ µÈ´Ù. ÀÌ Çö»óÀº Àڿܼ± ±¤¿øÀ» »ç¿ëÇÑ ¹°Áú ºÐ¼® µî¿¡ ÀÌ¿ëµÈ´Ù.
  • selective angiograph
    ¼±ÅÃÀû Ç÷°ü Á¶¿µ »çÁø
  • selective arteriography
    ¼±ÅÃÀû µ¿¸Æ Á¶¿µ¼ú
  • selective deficiencies of immunoglobulin
    ¼±ÅÃÀû ¸é¿ª ±Û·ÎºÒ¸° °áÇÌÁõ
    ´Ù¸¥ ¸é¿ª ±Û·ÎºÒ¸°Àº Á¤»óÀ̰ųª Áõ°¡µÇ¸é¼­ Çϳª ¶Ç´Â µÎ Á¾·ùÀÇ ¸é¿ª ±Û·ÎºÒ¸°ÀÌ °áÇ̵Ǿî ÀÖ´Â °æ¿ì·Î ´ëÇ¥ÀûÀÎ ÁúȯÀ¸·Î´Â IgA °áÇÌÁõ, IgM °áÇÌÁõ, IgG ¾Æ±º °áÇÌÁõ µîÀÌ ÀÖ´Ù.
  • selective excitaion
    ¼±Åà ¿©±â
  • selective grinding
    ¼±Åà »èÁ¦, ¼±ÅÃÀû ±³ÇÕ Á¶Á¤
    ÀÏÁ¤ÇÑ ¿ø¸®¿¡ µû¶ó Ä¡¾Æ¸¦ »èÁ¦ÇÏ¿© ±³ÇÕ¸é ÇüŸ¦ ¼öÁ¤ÇÏ´Â °ÍÀÌ´Ù. Áï ±³ÇÕÁö¿¡ ÀÇÇÏ¿© Ç¥½ÃµÇ´Â Á¡À̳ª ºÎÀ§¸¦ ¼±ÅÃÀûÀ¸·Î Ä¡¾ÆÀÇ ±³ÇÕ¸éÀ» »èÁ¦Çϰí Á¶Á¤ÇÏ´Â ¼ú½ÄÀÌ´Ù.
  • selective local anesthetic blockade
    ¼±ÅÃÀûÀÎ ±¹¼Ò ¸¶Ãë
  • selective pressure impression
    ¼±Åà °¡¾Ð Àλó
    ´Ù¸¥ ºÎÀ§º¸´Ù ¾î¶² ƯÁ¤ÇÑ ºÎÀ§¿¡ ÃÖÁ¾ Àλó Àç·á°¡ µé¾î°¥ ÃæºÐÇÑ °ø°£À» Æ®·¹ÀÌ¿¡ Á¦°øÇÑ ´ÙÀ½ ÀλóÀ» üµæÇÏ´Â ¹æ¹ý.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
bias <statistics> In a clinical trial, bias refers to effects that a conclusion that may be incorrect as, for example, when a researcher or patient knows what treatment is being given. To avoid bias, a blinded study may be done.
Any deviation of results or inferences from the truth, or processes leading to such deviation.
Bias can result from several sources: one-sided or systematic variations in measurement from the true value (systematic error); flaws in study design; deviation of inferences, interpretations, or analyses based on flawed data or data collection; etc. There is no sense of prejudice or subjectivity implied in the assessment of bias under these conditions.
(27 Jun 1999)
publication bias The influence of study results on the chances of publication and the tendency of investigators, reviewers, and editors to submit or accept manuscripts for publication based on the direction or strength of the study findings. Publication bias has an impact on the interpretation of clinical trials and meta-analyses. Bias can be minimised by insistence by editors on high-quality research, thorough literature reviews, acknowledgement of conflicts of interest, modification of peer review practices, etc.
(12 Dec 1998)
selection bias The introduction of error due to systematic differences in the characteristics between those selected and those not selected for a given study. In sampling bias, error is the result of failure to ensure that all members of the reference population have a known chance of selection in the sample.
(12 Dec 1998)
insurance selection bias Adverse of favourable selection bias exhibited by insurers or enrollees resulting in disproportionate enrollment of certain groups of people.
(12 Dec 1998)
internal bias Applied to the motile behaviour of crawling cells that, in the short term, show persistence and do not behave as true random walkers. Any intrinsic regulation of the random motile behaviour of the cell could be considered as internal bias.
(18 Nov 1997)
median survival <statistics> Median means the middle value. An equal number of people live longer as die earlier than the median.
(16 Dec 1997)
cell survival The span of viability of a cell characterised by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
(12 Dec 1998)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
survival 1. A living or continuing longer than, or beyond the existence of, another person, thing, or event; an outliving.
2. Any habit, usage, or belief, remaining from ancient times, the origin of which is often unknown, or imperfectly known. "The close bearing of the doctrine of survival on the study of manners and customs." (Tylor) Survival of the fittest.
<biology> See Natural selection, under Natural.
Origin: From Survive.
Source: Websters Dictionary
(01 Mar 1998)
survival analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
(12 Dec 1998)
survival rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
(12 Dec 1998)
survival time The period elapsing between the completion or institution of any procedure and death, the life-span of biologically or physically marked erythrocytes or other cells.
(05 Mar 2000)
disease-free survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
(12 Dec 1998)
tissue survival The span of viability of a tissue or an organ.
(12 Dec 1998)
five year survival rate The proportion of patients still alive five years after a diagnosis or form of treatment is completed. Usually applied to statistics of survival of cancer patients, since after five years, recurrences are much less likely to occur.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival
    »ì¾Æ ³²À½
  • survival
    ÀÜÁ¸;»ì¾Æ³²À½;»ýÁ¸ÀÚ;ÀÜÁ¸¹°;¿¹ºÎÅÍÀÇ Ç³½À(½Å¾Ó)
  • selective
    ¼±ÅÃÀÇ
  • Selective Service
    Àǹ« º´¿ª
  • selective
    ¼±ÅÃÀûÀÎ;µµÅÂÀÇ;¼±ÅÃÇÑ;ºÐ¸®½ÄÀÇ
  • bias
    »ç¼±
  • bias
    »ç¼±;¹ÙÀ̾;°æ»ç;°æÇâ;¼ºº®-±â¿ïÀÌ´Ù;Ä¡¿ìÄ¡°ÔÇÏ´Ù;Æí°ßÀ» °®´Ù
  • forward bias
    ¼ø ¹ÙÀ̾(¹ÝµµÃ¼ ¼ÒÀÚ¿¡ Àü·ù°¡ È帣´Â ¹æÇâÀ¸·Î °Å´Â)
  • grid bias
    ±×¸®µå ¹ÙÀ̾
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á